arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Dianthus Therapeutics, Inc.

DNTH Health Care Biotechnology: Pharmaceutical Preparations
$106.75
▼ -1.2% Today
as of Sep 4, 16:48 ET
Last 30 days +6.39% Jul 28 → Sep 04
$100.46 $104.62 $108.78 $112.95 $117.11 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$107.06
High
$109.61
Low
$105.65
Volume
$638,468
Avg Vol
$883,182
Mkt Cap
$6.1B
P/E (TTM)
—
Beta
—
52w High
$117.88
52w Low
$25.00
Div Yield
—
Shares Out
$55M

Recent Press Releases & News last 60 days · 11 items

Sep 5 · 11:30 Insider Monkey
Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen
Sep 4 · 09:52 MT Newswires
Citigroup Initiates Dianthus Therapeutics at Buy With $156 Price Target
Sep 2 · 21:00 PR GlobeNewswire
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
▸ Show all 11 press releases & news Free account →

Overview

52-week range
$25
$118
88% of range
Avg surprise (last 3)
+9.9%
Avg reaction (last 2)
+1.8%
100% positive
Latest IV / EM
52%
EM ±8.1% · $105 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-12.73$-9.68$-6.62$-3.56$-0.51 Actual $-8.10Actual $-12.73Actual $-3.78Actual $-0.54Actual $-0.51Actual $-0.74Actual $-0.82Est $-0.86Actual $-0.88Est $-0.86Actual $-0.97Actual $-0.85Est $-1.17Actual $-0.90 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-50M$-37M$-24M$-11M$2M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.90 — — — — financials
Tue May 5, 2026Mar/2026 $-0.85 $-1.17 +27.4% -3.7% +1.0% earnings
Tue Sep 30, 2025Sep 2025 $-0.97 — — — — financials
Thu Aug 7, 2025Jun/2025 $-0.88 $-0.86 -2.3% — — earnings
Mon May 12, 2025Mar/2025 $-0.82 $-0.86 +4.7% — +2.5% earnings
Mon Sep 30, 2024Sep 2024 $-0.74 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.51 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.54 — — — — financials
Sat Sep 30, 2023Sep 2023 $-3.78 — — — — financials
Fri Jun 30, 2023Jun 2023 $-12.73 — — — — financials
Fri Mar 31, 2023Mar 2023 $-8.10 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue———$396,000$193,000$1M—$2M
Cost of revenue————————
Gross profit————————
Operating income$-61M$-47M—$-40M$-35M$-33M—$-30M
Net income$-50M$-41M—$-37M$-32M$-30M—$-25M
EPS (diluted)$-0.90$-0.85—$-0.97$-0.88$-0.82—$-0.74

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$111M$628M$51M$56M$13M$10M$23M$34M
Inventory————————
Total current assets$898M$1.12B$409M$414M$264M$271M$281M$287M
Total assets$1.21B$1.25B$531M$577M$326M$349M$374M$354M
Long-term debt————————
Total liabilities$41M$46M$38M$31M$23M$20M$22M$16M
Total equity$1.17B$1.20B$493M$546M$303M$329M$352M$338M

Implied volatility — last 90 days

48%75%102%130%157% Jun 07 — IV 66% · EM ±9.2%Jun 08 — IV 69% · EM ±9.1%Jun 09 — IV 72% · EM ±9.0%Jun 10 — IV 77% · EM ±9.1%Jun 11 — IV 74% · EM ±8.2%Jun 12 — IV 101% · EM ±10.4%Jun 15 — IV 132% · EM ±9.6%Jun 16 — IV 116% · EM ±6.8%Jun 17 — IV 158% · EM ±6.6%Jun 19 — IV 59% · EM ±13.1%Jun 22 — IV 59% · EM ±12.3%Jun 23 — IV 60% · EM ±12.2%Jun 24 — IV 57% · EM ±11.4%Jun 25 — IV 59% · EM ±11.5%Jun 26 — IV 52% · EM ±10.0%Jun 29 — IV 58% · EM ±10.2%Jun 30 — IV 57% · EM ±9.9%Jul 01 — IV 53% · EM ±8.9%Jul 02 — IV 52% · EM ±8.4%Jul 03 — IV 54% · EM ±8.4%Jul 06 — IV 58% · EM ±8.1%Jul 07 — IV 56% · EM ±7.4%Jul 08 — IV 57% · EM ±7.2%Jul 09 — IV 61% · EM ±7.2%Jul 10 — IV 79% · EM ±8.7%Jul 13 — IV 81% · EM ±6.8%Jul 14 — IV 79% · EM ±5.7%Jul 15 — IV 86% · EM ±5.1%Jul 16 — IV 103% · EM ±4.3%Jul 20 — IV 60% · EM ±14.2%Jul 21 — IV 63% · EM ±14.6%Jul 22 — IV 62% · EM ±14.2%Jul 23 — IV 60% · EM ±13.6%Jul 24 — IV 63% · EM ±13.9%Jul 27 — IV 62% · EM ±13.0%Jul 28 — IV 62% · EM ±12.7%Jul 29 — IV 63% · EM ±12.5%Jul 30 — IV 65% · EM ±12.7%Jul 31 — IV 60% · EM ±11.6%Aug 03 — IV 61% · EM ±10.8%Aug 04 — IV 66% · EM ±11.4%Aug 05 — IV 60% · EM ±10.0%Aug 06 — IV 57% · EM ±9.3%Aug 07 — IV 58% · EM ±9.1%Aug 10 — IV 59% · EM ±8.2%Aug 11 — IV 55% · EM ±7.3%Aug 12 — IV 61% · EM ±7.7%Aug 13 — IV 57% · EM ±6.7%Aug 14 — IV 60% · EM ±6.6%Aug 17 — IV 68% · EM ±5.7%Aug 18 — IV 76% · EM ±5.5%Aug 19 — IV 85% · EM ±5.0%Aug 20 — IV 118% · EM ±4.9%Aug 24 — IV 57% · EM ±11.8%Aug 25 — IV 57% · EM ±11.7%Aug 26 — IV 54% · EM ±10.8%Aug 27 — IV 48% · EM ±9.4%Aug 28 — IV 50% · EM ±9.6%Aug 31 — IV 55% · EM ±9.8%Sep 01 — IV 53% · EM ±9.1%Sep 02 — IV 52% · EM ±8.6%Sep 03 — IV 53% · EM ±8.6%Sep 04 — IV 52% · EM ±8.1%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in